Literature DB >> 24166228

Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system.

G Niklas Norén1, Tomas Bergvall, Patrick B Ryan, Kristina Juhlin, Martijn J Schuemie, David Madigan.   

Abstract

BACKGROUND: Observational healthcare data offer the potential to identify adverse drug reactions that may be missed by spontaneous reporting. The self-controlled cohort analysis within the Temporal Pattern Discovery framework compares the observed-to-expected ratio of medical outcomes during post-exposure surveillance periods with those during a set of distinct pre-exposure control periods in the same patients. It utilizes an external control group to account for systematic differences between the different time periods, thus combining within- and between-patient confounder adjustment in a single measure.
OBJECTIVES: To evaluate the performance of the calibrated self-controlled cohort analysis within Temporal Pattern Discovery as a tool for risk identification in observational healthcare data. RESEARCH
DESIGN: Different implementations of the calibrated self-controlled cohort analysis were applied to 399 drug-outcome pairs (165 positive and 234 negative test cases across 4 health outcomes of interest) in 5 real observational databases (four with administrative claims and one with electronic health records). MEASURES: Performance was evaluated on real data through sensitivity/specificity, the area under receiver operator characteristics curve (AUC), and bias.
RESULTS: The calibrated self-controlled cohort analysis achieved good predictive accuracy across the outcomes and databases under study. The optimal design based on this reference set uses a 360 days surveillance period and a single control period 180 days prior to new prescriptions. It achieved an average AUC of 0.75 and AUC >0.70 in all but one scenario. A design with three separate control periods performed better for the electronic health records database and for acute renal failure across all data sets. The estimates for negative test cases were generally unbiased, but a minor negative bias of up to 0.2 on the RR-scale was observed with the configurations using multiple control periods, for acute liver injury and upper gastrointestinal bleeding.
CONCLUSIONS: The calibrated self-controlled cohort analysis within Temporal Pattern Discovery shows promise as a tool for risk identification; it performs well at discriminating positive from negative test cases. The optimal parameter configuration may vary with the data set and medical outcome of interest.

Entities:  

Mesh:

Year:  2013        PMID: 24166228     DOI: 10.1007/s40264-013-0095-x

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  20 in total

1.  Safety surveillance of longitudinal databases: further methodological considerations.

Authors:  Martijn J Schuemie
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-06       Impact factor: 2.890

Review 2.  Role of postmarketing surveillance in contemporary medicine.

Authors:  Janet Woodcock; Rachel E Behrman; Gerald J Dal Pan
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

3.  Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system.

Authors:  Patrick B Ryan; Martijn J Schuemie; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

4.  The case-crossover design: a method for studying transient effects on the risk of acute events.

Authors:  M Maclure
Journal:  Am J Epidemiol       Date:  1991-01-15       Impact factor: 4.897

5.  Quality criteria for early signals of possible adverse drug reactions.

Authors:  I R Edwards; M Lindquist; B E Wiholm; E Napke
Journal:  Lancet       Date:  1990-07-21       Impact factor: 79.321

6.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

7.  Disproportionality methods for pharmacovigilance in longitudinal observational databases.

Authors:  Ivan Zorych; David Madigan; Patrick Ryan; Andrew Bate
Journal:  Stat Methods Med Res       Date:  2011-08-30       Impact factor: 3.021

8.  Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines.

Authors:  J L Carson; B L Strom; A Duff; A Gupta; M Shaw; F E Lundin; K Das
Journal:  Ann Intern Med       Date:  1993-10-01       Impact factor: 25.391

Review 9.  Defining a reference set to support methodological research in drug safety.

Authors:  Patrick B Ryan; Martijn J Schuemie; Emily Welebob; Jon Duke; Sarah Valentine; Abraham G Hartzema
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

10.  Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system.

Authors:  R Harpaz; W DuMouchel; P LePendu; A Bauer-Mehren; P Ryan; N H Shah
Journal:  Clin Pharmacol Ther       Date:  2013-02-11       Impact factor: 6.875

View more
  22 in total

1.  How Confident Are We about Observational Findings in Healthcare: A Benchmark Study.

Authors:  Martijn J Schuemie; M Soledad Cepeda; Marc A Suchard; Jianxiao Yang; Yuxi Tian; Alejandro Schuler; Patrick B Ryan; David Madigan; George Hripcsak
Journal:  Harv Data Sci Rev       Date:  2020-01-31

2.  Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases.

Authors:  Martijn J Schuemie; Rosa Gini; Preciosa M Coloma; Huub Straatman; Ron M C Herings; Lars Pedersen; Francesco Innocenti; Giampiero Mazzaglia; Gino Picelli; Johan van der Lei; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

Review 3.  Desideratum for evidence based epidemiology.

Authors:  J Marc Overhage; Patrick B Ryan; Martijn J Schuemie; Paul E Stang
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

4.  Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey.

Authors:  Paul E Stang; Patrick B Ryan; J Marc Overhage; Martijn J Schuemie; Abraham G Hartzema; Emily Welebob
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

5.  A comparison of the empirical performance of methods for a risk identification system.

Authors:  Patrick B Ryan; Paul E Stang; J Marc Overhage; Marc A Suchard; Abraham G Hartzema; William DuMouchel; Christian G Reich; Martijn J Schuemie; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

6.  Evaluating performance of risk identification methods through a large-scale simulation of observational data.

Authors:  Patrick B Ryan; Martijn J Schuemie
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

7.  A Novel Approach to Visualize Risk Minimization Effectiveness: Peeping at the 2012 UK Proton Pump Inhibitor Label Change Using a Rapid Cycle Analysis Tool.

Authors:  Rachel E Sobel; William Blackwell; David M Fram; Andrew Bate
Journal:  Drug Saf       Date:  2019-11       Impact factor: 5.606

8.  Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance.

Authors:  G Niklas Norén; Ola Caster; Kristina Juhlin; Marie Lindquist
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606

9.  Adverse Drug Reaction Discovery from Electronic Health Records with Deep Neural Networks.

Authors:  Wei Zhang; Peggy Peissig; Zhaobin Kuang; David Page
Journal:  Proc ACM Conf Health Inference Learn (2020)       Date:  2020-04

10.  Pharmacovigilance via Baseline Regularization with Large-Scale Longitudinal Observational Data.

Authors:  Zhaobin Kuang; Peggy Peissig; Vítor Santos Costa; Richard Maclin; David Page
Journal:  KDD       Date:  2017-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.